Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Sep 15, 2023; 15(9): 1505-1519
Published online Sep 15, 2023. doi: 10.4251/wjgo.v15.i9.1505
Published online Sep 15, 2023. doi: 10.4251/wjgo.v15.i9.1505
Potent therapeutics | Cancer Hallmarks |
TGF-β pathway inhibitors HGF; Met pathway inhibitors | Activating invasion/metastasis |
JAK/STAT pathway inhibitors; BTK inhibitors; Src inhibitors; COX-2 inhibitors | Tumour-promoting inflammation |
NRF2 pathway inhibitors; HIF-1 pathway inhibitors; PKCδ-PKD1 inhibitors; Amino acid transporter inhibitors; α-Glucosidase inhibitors | Deregulating cellular metabolism |
EGF pathway inhibitors; Ras/Raf/ MEK/ERK pathway inhibitors; PI3K/AKT/mTOR pathway inhibitors; Wnt pathway inhibitors; PDGF pathway inhibitors; SCF/c-Kit pathway inhibitors; ALK pathway inhibitors; Hedgehog pathway inhibitors | Sustaining proliferative signalling |
IGF pathway inhibitors; NF-κB pathway inhibitors | Resisting apoptosis |
VEGF pathway inhibitors | Inducing angiogenesis |
Shh pathway inhibitors; FAK inhibitors; Src inhibitors; EGFR inhibitors | Expansive desmoplasia |
Aurora kinase inhibitors; Cyclin-dependent kinase inhibitors | Eluding growth suppressors |
PD-L1 inhibitors; CTLA-4 inhibitors | Avoiding immune destruction |
PARP inhibitors Photodynamic agents; Bromodomain inhibitors; HDAC inhibitors | Genome instability and damage |
- Citation: Bararia A, Das A, Mitra S, Banerjee S, Chatterjee A, Sikdar N. Deoxyribonucleic acid methylation driven aberrations in pancreatic cancer-related pathways. World J Gastrointest Oncol 2023; 15(9): 1505-1519
- URL: https://www.wjgnet.com/1948-5204/full/v15/i9/1505.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i9.1505